Avatrombopag achieved a durable platelet response in 28% of pediatric patients with persistent or chronic immune thrombocytopenia (ITP), compared to 0% with placebo.
81% of avatrombopag-treated patients showed at least two consecutive platelet responses versus none in the placebo group.
The safety profile was reassuring, with no deaths, thromboembolic events, or severe bleeding episodes.
Avatrombopag offers a convenient oral option with flexible administration and no dietary restrictions for children and adolescents with ITP.
Study Background and Disease Burden
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.